Compare EVO & HDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVO | HDL |
|---|---|---|
| Founded | 1993 | 2016 |
| Country | Germany | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2021 | 2024 |
| Metric | EVO | HDL |
|---|---|---|
| Price | $3.31 | $17.81 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 99.6K | 2.1K |
| Earning Date | 11-05-2025 | 11-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $887,396,457.00 | $820,865,000.00 |
| Revenue This Year | N/A | $11.22 |
| Revenue Next Year | $10.78 | $13.44 |
| P/E Ratio | ★ N/A | $58.53 |
| Revenue Growth | N/A | ★ 8.02 |
| 52 Week Low | $2.84 | $16.30 |
| 52 Week High | $5.10 | $30.00 |
| Indicator | EVO | HDL |
|---|---|---|
| Relative Strength Index (RSI) | 49.54 | 48.88 |
| Support Level | $2.89 | $17.51 |
| Resistance Level | $3.24 | $17.77 |
| Average True Range (ATR) | 0.09 | 0.36 |
| MACD | 0.04 | 0.12 |
| Stochastic Oscillator | 95.65 | 75.50 |
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Super Hi International Holding Ltd is an investment holding company and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan. It mission is to become a global integrated restaurant group, build the world's Chinese cuisine brand, and promote Chinese culinary heritage world-wide.